PMID- 18075269
OWN - NLM
STAT- MEDLINE
DCOM- 20080324
LR  - 20141120
IS  - 1660-2854 (Print)
IS  - 1660-2854 (Linking)
VI  - 5
IP  - 1
DP  - 2008
TI  - Intravenous polyclonal human immunoglobulins in multiple sclerosis.
PG  - 8-15
AB  - Intravenous immunoglobulin (IVIG) is an established therapy for demyelinating 
      diseases of the peripheral nervous system. IVIG exerts a number of effects that 
      may be beneficial in multiple sclerosis (MS). Four double-blind IVIG trials have 
      been performed in relapsing-remitting MS. A meta-analysis of the four trials has 
      shown that IVIG reduces the relapse rate and, possibly, disease progression. In 
      patients with a first episode of demyelinating disease, IVIG delays the time to 
      the second relapse and thereby to the diagnosis of definite MS. In patients with 
      an acute MS relapse, IVIG as add-on therapy to methylprednisolone does not make 
      remission of symptoms faster or more complete. IVIG does not seem to be of any 
      benefit to chronic visual or motor symptoms in MS. In secondary progressive MS, 
      IVIG has not shown any effect on disease progression, relapses or new magnetic 
      resonance imaging lesions. Experimental studies in the MS model experimental 
      autoimmune encephalomyelitis in rats demonstrate that IVIG has to be administered 
      at the time of induction of a relapse in order to be effective. In conclusion, 
      IVIG can be considered as a second-line treatment to approved therapies for 
      relapsing-remitting MS, but the ideal dosage of IVIG still needs to be 
      determined. In order to be a first-line treatment for MS, the beneficial effect 
      should be confirmed in a large-scale placebo-controlled survey, or in a study 
      comparing the effect with approved therapies for relapsing-remitting MS using 
      appropriate clinical and magnetic resonance imaging outcome measures.
CI  - Copyright (c) 2008 S. Karger AG, Basel.
FAU - Soelberg Sorensen, Per
AU  - Soelberg Sorensen P
AD  - Danish MS Research Center, Department of Neurology, Copenhagen University 
      Hospital, Rigshospitalet, Copenhagen, Denmark. pss@rh.dk
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Switzerland
TA  - Neurodegener Dis
JT  - Neuro-degenerative diseases
JID - 101189034
RN  - 0 (Antibodies)
RN  - 0 (Immunoglobulins, Intravenous)
SB  - IM
MH  - Animals
MH  - Antibodies/*pharmacology/*therapeutic use
MH  - Clinical Trials as Topic/statistics & numerical data
MH  - Disease Progression
MH  - Encephalomyelitis, Autoimmune, Experimental/drug 
      therapy/immunology/physiopathology
MH  - Humans
MH  - Immunoglobulins, Intravenous/*pharmacology/*therapeutic use
MH  - Multiple Sclerosis/*drug therapy/*immunology/physiopathology
MH  - Secondary Prevention
MH  - Treatment Outcome
RF  - 42
EDAT- 2007/12/14 09:00
MHDA- 2008/03/25 09:00
CRDT- 2007/12/14 09:00
PHST- 2006/05/29 00:00 [received]
PHST- 2007/05/14 00:00 [accepted]
PHST- 2007/12/14 09:00 [pubmed]
PHST- 2008/03/25 09:00 [medline]
PHST- 2007/12/14 09:00 [entrez]
AID - 000109932 [pii]
AID - 10.1159/000109932 [doi]
PST - ppublish
SO  - Neurodegener Dis. 2008;5(1):8-15. doi: 10.1159/000109932.